D3S-001 Demonstrated Significantly Improved Covalency and Rapid Target Engagement Not Affected by Growth Factors, Potentially Depleting Cellular Active KRAS in Multiple Preclinical Models Overcame ...

While single-cell RNA sequencing has advanced our understanding of cell fate, identifying molecular hallmarks of potency—a cell’s ability to differentiate into other cell types—remains a challenge.

Cellular rejuvenation shows great promise for treating age-related diseases and disabilities. However, the underlying molecular mechanisms and how and where information for youthful, healthy cells ...

Approved biological products are required to be accompanied by analytical tests to demonstrate safety, purity, and potency. Manufacturing and testing processes for approved products are validated and ...

Chimeric Antigen Receptor (CAR) T-cell immunotherapy holds enormous potential for the treatment of cancer. The goal of cell therapy is to not only achieve tumor reduction but also to activate an ...

A new study posted in the preprint server bioRxiv* aimed to analyze the qualitative and quantitative impact of spike (S)-induced humoral immunity along with its antibody-dependent cellular ...

There are unique challenges when it comes to cell therapy products, including ensuring the reproducibility and consistency of product lots. These specific concerns arise from the inherent variability ...

Researchers from Janssen Pharmaceutica NV have reported the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs) as potential therapeutic candidates against HBV infection.

Potency is a critical quality attribute of biological products, defined by the US FDA as the specific ability of the product to cause the required therapeutically clinical benefit. Potency assay will ...